- Home
- RERE vs FULC Comparison
RERE vs FULC Comparison
Compare RERE & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | FULC |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 859.3M | 707.9M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RERE | FULC |
|---|---|---|
| Price | $5.85 | $9.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | ★ 1.1M | 675.2K |
| Earning Date | 03-10-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $2,759,212,837.00 | N/A |
| Revenue This Year | $30.77 | N/A |
| Revenue Next Year | $25.01 | N/A |
| P/E Ratio | $35.67 | ★ N/A |
| Revenue Growth | 27.95 | ★ 2752.05 |
| 52 Week Low | $2.00 | $2.32 |
| 52 Week High | $6.47 | $15.74 |
Technical Indicators
Market Signals| Indicator | RERE | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 40.43 |
| Support Level | $5.38 | $9.52 |
| Resistance Level | $6.00 | $10.51 |
| Average True Range (ATR) | 0.26 | 0.67 |
| MACD | -0.06 | -0.09 |
| Stochastic Oscillator | 42.62 | 11.02 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.